ClinicalTrials.gg
RecruitingNCT07356518Updated Apr 27, 2026

Telehealth and Remote Blood Pressure

An interventional study of Telehealth visits and In-person visits in Hypertension and Hypertension in Pregnancy, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Hypertension by Wake Forest University Health Sciences — 4 open to participants now, 7 under way, none of them phase 3. Hypertension · Wake Forest University Health Sciences.

Planned enrollment
7th of 20
60 · median 41
Started
2026
with 2 others
No phase
17 of 25
3 open now
Registered
24th of 25
by date

Among the 25 studies in Hypertension by Wake Forest University Health Sciences, this one is the 7th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2026, is one of 17 with no phase, and was the 24th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

4 of the 25 studies in Hypertension by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hypertension by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

The purpose of this research study is to compare the management of chronic hypertension during pregnancy using telehealth visits with blood pressure telemonitoring and health coaching as compared to standard in person clinic visits. The study involves pregnant woman aged 18-45 who are receiving care for chronic hypertension. Participation in this research study will last until their baby is delivered. The number of in-person clinic visits depends on the participant's treatment assignment. Those assigned to telehealth visits will have telehealth visits alternating with clinic visits every two weeks until the end of pregnancy week 31. Those assigned to telehealth visits will also have five sessions with a health coach via telephone or video from the time of enrollment until the end of pregnancy week 36.

Read the detailed description

Hypertension (HTN) in pregnancy requires weekly or bi-weekly in-person visits. Telehealth visits with remote blood pressure (BP) telemonitoring may be an alternative to frequent in-person visits improve adherence. However, the feasibility of this approach in pregnancy is lacking and studies are limited on the use of remote BP telemonitoring in chronic HTN (cHTN) during pregnancy. A digital health platform for BP management in pregnant women at risk for preeclampsia (women with cHTN, prior preeclampsia or kidney disease) found fewer admissions for HTN or suspected preeclampsia in the intervention compared to usual care. There is a critical need to investigate the feasibility (willingness and adherence), and safety of this intervention. Without ascertaining the feasibility of telehealth and remote BP monitoring, it remains a challenge to tackle the no-show rates and suboptimal medication adherence during pregnancy.

Objectives Aim 1: To determine the feasibility of incorporating telehealth clinic visits with remote BP telemonitoring alternating with in-person clinic visits in the management of cHTN in pregnancy in the clinic by evaluating willingness to enroll, completion rate and adherence versus standard care (in-person clinic visits alone). This working hypothesis is that this approach will be as feasible as standard care.

Aim 2: To explore safety outcomes of telehealth clinic visits combined with blood pressure remote telemonitoring alternating with in-person clinic visits in the management of chronic hypertension in pregnant patients in the clinic by measuring the incidence of hypotension, syncope or hospitalization/emergency room visits for severe HTN compared to standard care. The working hypothesis is that this approach will be comparable in safety to standard care.

03

Conditions studied

  • Hypertension
  • Hypertension in Pregnancy

Keywords

  • high blood pressure
  • pre-eclampsia
  • hypertension during pregnancy
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • prior diagnosis of Chronic hypertension (cHTN)
  • Pregnant women
  • Known: documented diagnosis or on antihypertensive medication prior to pregnancy

Exclusion criteria

Exclusion Criteria:

  • Any significant chronic medical or psychiatric illness that, in the investigator's opinion, would prevent participation in the study
  • Cardiac disorders: cardiomyopathy, angina, Coronary Artery Disease (CAD)
  • Current substance abuse disorder
  • Multifetal pregnancy
  • Participation in another study without prior approval
  • Plan to deliver outside Atrium Health Wake Forest Baptist
  • Prior stroke
  • Severe hypertension
  • Suspected or known fetal major structural/chromosomal abnormality or fetal demise
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Telehealth Cycle

    Participants in this arm will be provided telehealth visits in addition to the blood pressure telemonitoring.

    Behavioral: Telehealth visits · Behavioral: In-person visits

  • Active comparator
    Standard of Care

    In person clinic visits

    Behavioral: In-person visits

Interventions

  • BehavioralTelehealth visits

    remote visits with participants

  • BehavioralIn-person visits

    standard of care visits with care provider in person

06

What researchers measure

Primary outcomes

  1. Feasibility of telehealth with remote BP telemonitoring compared to standard care

    willingness to enroll (number of patients enrolled divided by number of patients reached), study completion rate, adherence compared to standard care). Adherence will be defined as taking medication at least ≥80% of the time, recording ≥70% of weekly BP readings in the intervention group only and completing ≥70% of antenatal telehealth/clinic visits.

    Time frame: Gestational Week 31

  2. Safety of telehealth combined with telemonitoring compared to standard care

    The number of adverse events reported (hypotension, syncope or hospitalization/emergency room visit for severe HTN

    Time frame: Gestational Week 31

Secondary outcomes

  1. Patient satisfaction Scores

    at the end of 31 weeks, each participant will complete a patient research satisfaction survey - Strongly disagree 0, disagree 1, neither agree nor disagree 2, agree 3, strongly agree 4

    Time frame: Gestational Week 31

  2. Clinical team member (Medical Assistant, Nursing staff, Medical Provider, Scheduler) satisfaction Scores

    at the end of 31 weeks, each provider of record for each participant will be invited to complete a research satisfaction survey. Nurses, medical assistants, schedulers at the Comprehensive Fetal Care Center who have participated in the telehealth visit with remote monitoring will be invited to complete a research satisfaction survey - Strongly disagree 0, disagree 1, neither agree nor disagree 2, agree 3, strongly agree 4

    Time frame: Gestational Week 31

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underline the results reported in this article, after de-identification (text, tables and appendices)

Supporting information: Study protocol

Time frame: Beginning 12 months and ending 36 months following article publication.

Access criteria: Investigators whose proposed use of data has been approved by an independent review committee identified for this purpose. For what types of analysis: to achieve aims of the approval proposal and for individual participant data meta-analysis. By what mechanism will data become available: Proposals may be submitted up to 36 months. After 36 months the data will be available in our University's data warehouse.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 8 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 21, 2026
StartActual
Apr 22, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07356518
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Apr 22, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 27, 2026

Study contacts

Ejiro Obioma, MBBS MMCi
Contact
Ejiro.Obioma@Advocatehealth.org
704-355-2000
Aderonke Adeniyi, MD, MS
Contact
aderonke.adeniyi@advocatehealth.org
337 713 2278
Aderonke O Adeniyi, MD, MS
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion